Regulus Reports Second Quarter 2017 Financial Results and Recent Events

LA JOLLA, Calif., Aug. 1, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the six months ended June 30, 2017 and recent...